Tag: MedImmune LLC (MEDI)

Inovio Is in Much Better Shape Than Six Months Ago

Inovio Is in Much Better Shape Than Six Months Ago

INOVIO Inovio Pharmaceuticals (INO) is much worth looking at now than 6 months ago. The deal signed between MedImmune, AstraZeneca’s development arm, and Inovio Pharmaceuticals says something. The DEAL MedImmune acquired exclusive rights to Inovio’s INO-3112 immunotherapy against cancers caused by human papillomavirus (HPV) types 16 and 18, which account for more than 70 percent of cervical pre-cancers and cancers. INO-3112 is in Phase 1/2 clinical …
Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination

Astrazeneca Selects Mirati Therapeutics Drug for Its Cancer Immunotherapy Combination

In The NEWS IMMUNOTHERAPY MIRATI THERAPEUTICS Mirati Therapeutics (MRTX) is an oncology company focusing on genetic and epigenetic drivers of cancer. The firm’s clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of solid tumors, including lung, head and neck, and gastric cancers; MGCD516, a kinase inhibitor, which is in Phase 1 clinical …